Details of the Drug

General Information of Drug (ID: DMCR1MV)

• Drug Name: Itraconazole
• Synonyms: Canadiol; Hyphanox; ITCZ; ITZ; Intraconazole; Itraconazol; Itraconazolum; Itrizole; Oriconazole; Orungal; Prokanazol; Sempera; Spherazole; Sporal; Sporanos; Sporanox; Sporonox; Triasporn; Itraconazol [Spanish]; Itraconazole oral solution; Itraconazolum [Latin]; R 51211; Cis-Itraconazole; Itraconazole & Bovine Lactoferrin; Itraconazole & Nyotran; Itrizole (TN); R-51211; Sporanox (TN); Itraconazole & Nyotran(Liposomal Nystatin); Itraconazole (JAN/USAN); Oriconazole, R51211, Sporanox; Itraconazole [USAN:BAN:INN:JAN]; (+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one; (1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one

Indication

Disease Entry	ICD 11	Status	REF
Aspergillosis	1F20	Approved	[1]
Blastomycosis	1F22	Approved	[1]
Fungal infection	1F29-1F2F	Approved	[2]
Fusariosis	N.A.	Approved	[1]
Histoplasmosis	N.A.	Approved	[1]
Invasive candidiasis	1F23	Approved	[1]
Mycoses	1F2Z	Approved	[1]
Candidemia	1F23.3Y	Investigative	[1]
Esophageal candidiasis	N.A.	Investigative	[1]

• Therapeutic Class: Antifungal Agents
• Affected Organisms: Fungi, yeast and protozoans
• ATC Code:
  J02AC02: Itraconazole
  J02AC: Triazole and tetrazole derivatives
  J02A: ANTIMYCOTICS FOR SYSTEMIC USE
  J02: ANTIMYCOTICS FOR SYSTEMIC USE
  J: ANTIINFECTIVES FOR SYSTEMIC USE
  J02AC02: Itraconazole
  J02AC: Triazole and tetrazole derivatives
  J02A: ANTIMYCOTICS FOR SYSTEMIC USE
  J02: ANTIMYCOTICS FOR SYSTEMIC USE
  J: ANTIINFECTIVES FOR SYSTEMIC USE
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 3:
  Molecular Weight (mw); 705.6
  Logarithm of the Partition Coefficient (xlogp); 5.7
  Rotatable Bond Count (rotbonds); 11
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 9
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
  Bioavailability: The bioavailability of drug is 55% []
  Clearance: The drug present in the plasma can be removed from the body at the rate of 5.1 mL/min/kg [4]
  Elimination: 0.03% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 21 hours [4]
  Metabolism: The drug is metabolized via the liver []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 14.17132 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.002% [4]
  Vd: The volume of distribution (Vd) of drug is 796 +/- 185 L []
  Water Solubility: The ability of drug to dissolve in water is measured as 0.000001 mg/mL [3]
• Chemical Identifiers:
  Formula: C35H38Cl2N8O4
  IUPAC Name: 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
  Canonical SMILES: CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl
  InChI: InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1
  InChIKey: VHVPQPYKVGDNFY-ZPGVKDDISA-N
• Cross-matching ID:
  PubChem CID: 55283
  ChEBI ID: CHEBI:6076
  CAS Number: 84625-61-6
  UNII: 304NUG5GF4
  DrugBank ID: DB01167
  TTD ID: D0V4IB
  VARIDT ID: DR00687
  INTEDE ID: DR0895
  ACDINA ID: D00337
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Cytochrome P450 51 (Candi ERG11)	TTTSOUD	CP51_CANAL	Modulator	[6]
Hedgehog signaling pathway (HS pathway)	TT4LXBC	NOUNIPROTAC	Inhibitor	[7]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[10]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)	OTG2T749	CP24A_HUMAN	Gene/Protein Processing	[11]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Gene/Protein Processing	[12]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[13]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[14]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[15]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[16]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Gene/Protein Processing	[17]
Interleukin-5 (IL5)	OTAFPSCO	IL5_HUMAN	Gene/Protein Processing	[17]
Lanosterol 14-alpha demethylase (CYP51A1)	OTAYHG9C	CP51A_HUMAN	Drug Response	[18]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Gene/Protein Processing	[19]

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 131 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JK1	CTRP2	4.2467	10.3399	1.0929	12.1943
MEC1	CTRP2	5.1039	8.9995	2.4183	5.2738
JM1	CTRP2	5.0352	9.4999	2.1247	6.5797
EoL-1	CTRP2	-0.4381	4.2023	-0.8832	31.583
CML-T1	CTRP2	-0.0269	1.5794	-0.0321	27.4012
AML-193	CTRP2	0.1311	1.9706	0.1164	26.3814
KMS-26	CTRP2	0.1871	3.5902	-0.0443	26.7508
Ku812	CTRP2; CTRP1	0.3291	12.7659	-3.2054	37.7821
RPMI-8402	CTRP2	0.3336	3.832	0.0576	25.9343
KHM-1B	CTRP2	0.7467	5.8943	-0.1726	25.4868
NCO2	CTRP2	1.0156	7.0686	-0.3736	25.4074
PL21	CTRP2; CTRP1	1.1096	3.0588	1.0892	24.753
WSU-DLCL2	CTRP2; CTRP1	1.3427	3.176	1.3235	23.2923
BL-70	CTRP2; CTRP1	1.4546	3.1513	1.4402	22.5776
DEL	CTRP2	1.7346	4.4558	1.4104	16.809
KMS-12-BM	CTRP2	1.8578	8.1518	-0.0082	21.8261
NU-DUL-1	CTRP2; CTRP1	1.8754	3.9437	1.8135	20.098
MC116	CTRP2; CTRP1	1.897	2.4034	1.897	19.7665
THP-1	CTRP1	1.9568	4.7498	1.7525	45.0064
SU-DHL-1	CTRP2	1.9755	6.3528	0.9268	17.9805
KMS-34	CTRP2	2.1373	4.8628	1.7065	14.537
KMS-28BM	CTRP2	2.2861	6.0615	1.3733	15.4208
MOTN-1	CTRP2	2.4242	6.1763	1.4636	14.7063
MOLT-16	CTRP2	2.4262	5.2811	1.851	13.1809
EM-2	CTRP2	2.4618	10.3112	-0.4649	21.9488
SU-DHL-5	CTRP1	2.5387	5.1223	2.2909	37.4978
GDM-1	CTRP2; CTRP1	2.633	6.6934	1.8373	17.9111
KMS-11	CTRP2; CTRP1	2.7045	6.5493	1.9709	17.2458
LP-1	CTRP2; CTRP1	2.7629	8.7385	1.0755	20.3231
SKM-1	CTRP2; CTRP1	2.8107	4.6812	2.6972	14.4213
TALL-1 [Human adult T-ALL]	CTRP2	2.9017	9.6497	0.2654	18.2684
Daudi	CTRP2	2.9669	6.8315	1.6978	12.4232
U-937	CTRP2; CTRP1	3.1155	8.1138	1.7146	17.1625
SUP-T11	CTRP2	3.189	8.5912	1.0491	14.5519
KMS-18	CTRP2	3.3114	7.2324	1.8292	11.0901
KE-97	CTRP2; CTRP1	3.5627	7.486	2.4496	13.3629
RS4;11	CTRP2	3.7146	11.2597	0.1861	16.798
RPMI-8226	CTRP2; CTRP1	3.7272	7.5302	2.5922	12.4418
Mono-Mac-1	CTRP2	3.7517	8.3064	1.6921	10.714
GA-10	CTRP2	3.8456	10.3158	0.7695	14.2775
RCH-ACV	CTRP2	4.0053	9.7099	1.2075	12.1985
ALL-SIL	CTRP2	4.0206	7.8502	2.1501	8.2631
MV4-11	CTRP2	4.0434	18.0984	-2.9548	25.7492
OPM-2	CTRP2	4.131	14.6218	-1.1435	20.557
Pfeiffer	CTRP2	4.1586	12.787	-0.2032	17.3274
OCI-AML-3	CTRP2; CTRP1	4.1859	5.6287	3.907	6.4212
NOMO-1	CTRP2; CTRP1	4.203	7.2539	3.1862	9.0979
HEL 92.1.7	CTRP2	4.2235	9.0173	1.735	9.6057
A4/Fukuda	CTRP2	4.2593	7.3031	2.6205	5.8367
JVM-3	CTRP2	4.3151	8.4029	2.1164	7.8453
HPB-ALL	CTRP2	4.437	8.7334	2.049	7.9046
MOLP-2	CTRP2	4.4887	6.2394	3.3248	2.507
KYO-1	CTRP2	4.49	7.0369	2.9333	4.1237
ST486	CTRP2	4.5799	10.9495	1.0577	11.7135
TF-1	CTRP2	4.5852	9.0911	1.9874	7.8973
SET-2	CTRP2	4.6048	8.3306	2.3801	6.2309
HT	CTRP2; CTRP1	4.613	9.195	2.6084	10.4972
SUP-B15	CTRP2	4.6214	6.6827	3.2034	2.8007
JeKo-1	CTRP2	4.6295	7.1541	2.9791	3.7078
MOLP-8	CTRP2	4.7285	7.3995	2.9305	3.7528
Hs 611.T	CTRP2	4.7556	8.1548	2.5802	5.1515
BV-173	CTRP2	4.7603	8.6206	2.3543	6.0776
SU-DHL-4	CTRP2; CTRP1	4.7987	8.8683	2.9333	8.865
DB	CTRP2	4.8016	8.0608	2.6599	4.7497
OCI-Ly3	CTRP2	4.8051	6.9969	3.1786	2.6343
HL-60	CTRP2	4.8338	8.6263	2.406	5.7445
CMK	CTRP2	4.869	7.3383	3.0582	3.0271
OCI-Ly10	CTRP2; CTRP1	4.9121	6.4447	4.2401	3.5053
SUP-HD1	CTRP2	4.9272	8.4232	2.5733	4.91
EB1	CTRP2	4.9664	17.4787	-1.8905	21.2059
Mino	CTRP2	4.9845	7.1917	3.2041	2.2945
OCI-AML-2	CTRP2	4.9866	9.1827	2.2448	6.1642
K-562	CTRP2	4.9939	10.9251	1.3916	9.6398
P3HR-1	CTRP2; CTRP1	5.0193	7.4817	3.8143	4.9811
MOLM-6	CTRP2	5.0258	10.361	1.6942	8.3568
SIG-M5	CTRP2	5.0424	6.6674	3.4796	1.1957
L-540	CTRP2	5.0434	10.8223	1.4798	9.1996
RL	CTRP2	5.0442	8.8435	2.4519	5.227
AMO1	CTRP2; CTRP1	5.0489	6.8867	4.1367	3.6554
Karpas-422	CTRP2	5.0893	7.7897	2.9899	2.9974
HD-MY-Z	CTRP2	5.1116	8.2701	2.7758	3.8181
NALM-6	CTRP2	5.1454	12.4767	0.7386	11.972
Karpas-620	CTRP2	5.1604	8.0199	2.9274	3.1494
Reh	CTRP2	5.1886	7.3005	3.2794	1.7666
Ci-1	CTRP2	5.1977	5.9175	3.8549	0.0724
EHEB	CTRP2	5.2229	10.4863	1.7779	7.6976
EJM	CTRP2; CTRP1	5.2719	8.6236	3.4508	5.9671
NB4	CTRP2	5.2795	7.5064	3.2396	1.8135
SU-DHL-8	CTRP2	5.3624	7.4664	3.3049	1.4938
SU-DHL-10	CTRP2	5.3837	6.3354	3.7765	0.141
NCI-H929	CTRP2	5.3963	9.4254	2.4148	4.8636
MOLM-16	CTRP2; CTRP1	5.4043	9.3074	3.2152	6.6689
PF-382	CTRP2	5.4283	9.2366	2.5264	4.3751
Raji	CTRP2	5.4481	7.2097	3.4615	0.8977
SU-DHL-6	CTRP2	5.5144	7.0908	3.5427	0.6124
P31/FUJ	CTRP2	5.5162	10.2529	2.0989	5.9577
HDLM-2	CTRP2	5.5229	11.6292	1.4357	8.6045
Kasumi-1	CTRP2	5.5428	10.2779	2.1051	5.8944
KMS-20	CTRP2	5.6203	7.9686	3.2263	1.5205
SR	CTRP2	5.6405	8.1883	3.141	1.796
Ki-JK	CTRP2	5.647	19.6888	-2.4547	21.5468
Ri-1	CTRP2	5.7196	8.6623	2.9745	2.3086
OCI-AML-5	CTRP2	5.7516	11.2384	1.7858	6.8677
OCI-M1	CTRP2	5.7858	6.9336	3.7154	0.1321
L-428	CTRP2	5.8985	10.3368	2.3124	4.5966
REC-1	CTRP2	5.9207	8.4422	3.1814	1.4078
KO52	CTRP2	6.0283	10.8157	2.1706	4.9801
RPMI-6666	CTRP2	6.0757	7.7757	3.5221	0.3799
Jurkat	CTRP2	6.0939	14.4448	0.4708	11.443
Granta-519	CTRP2	6.153	7.7052	3.5791	0.246
JJN-3	CTRP2	6.1579	7.6854	3.5881	0.2297
L-363	CTRP2	6.1592	7.6068	3.6168	0.185
OCI-Ly19	CTRP2	6.1635	8.1862	3.4023	0.611
F-36P	CTRP2	6.1844	10.349	2.4836	3.6032
KMS-27	CTRP2	6.2128	14.0211	0.761	10.175
MOLT-13	CTRP2	6.2182	7.9269	3.5237	0.3239
M-07e	CTRP2	6.2738	8.1751	3.4538	0.4428
SK-MM-2	CTRP2	6.3134	15.2877	0.2166	12.0371
Kasumi-2	CTRP2	6.441	8.1117	3.5434	0.224
SUP-T1	CTRP2	6.4656	20.5067	-2.2343	19.5946
U266B1	CTRP2	6.5788	8.2064	3.5613	0.1679
MM1.S	CTRP2	6.5875	15.3876	0.3609	11.1018
MHH-CALL-4	CTRP2	6.7056	8.4077	3.5374	0.1727
Karpas-299	CTRP2	6.9084	14.685	0.915	8.612
KM-H2	CTRP2	7.0306	14.6586	1.0073	8.108
MHH-CALL-3	CTRP2	7.3583	9.7729	3.2981	0.3636
HEL	CTRP2	7.4123	18.3814	-0.5143	12.9445
ME1	CTRP2	7.9574	17.0034	0.4993	8.7589
Mono-Mac-6	CTRP2	7.9746	10.6412	3.2218	0.3218
LAMA-84	CTRP2	9.7287	29.1087	-4.091	19.4866
KCL-22	CTRP2	11.0604	26.6411	-2.0435	12.9222

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE15	CTRP2	5.022	8.8301	2.4427	5.2986
TE8	CTRP2	6.0614	12.4735	1.4037	7.9271
KYSE-410	CTRP2; CTRP1	2.5882	5.3765	2.2696	16.5035
TE-9	CTRP2	4.2022	5.4579	3.4954	2.2738
TE-6	CTRP2	4.7532	8.4329	2.4416	5.7282
TE-5	CTRP2	4.8339	8.835	2.3034	6.1674
KYSE-140	CTRP2; CTRP1	4.9143	7.4382	3.7467	5.4438
EC-GI-10	CTRP2	4.9988	11.0009	1.3577	9.7682
TE-4	CTRP2	5.0395	7.1709	3.2485	2.0549
OE21	CTRP2	5.273	10.366	1.873	7.2332
OE19	CTRP2	5.7184	7.2356	3.5771	0.4139
TE-1	CTRP2	5.8963	8.3346	3.2145	1.3216
KYSE-70	CTRP2	6.1306	8.1575	3.399	0.6363
OE33	CTRP2	6.2097	8.051	3.4739	0.4265
KYSE-30	CTRP2	6.3108	8.919	3.1768	1.1293
KYSE-510	CTRP2	6.4376	12.6352	1.5776	6.7364
KYSE-520	CTRP2	6.5343	10.6251	2.5623	2.9477
KYSE-150	CTRP2	6.7185	7.9861	3.6846	0.0399
KYSE-450	CTRP2; CTRP1	6.729	11.5514	3.0768	5.2556
KYSE-180	CTRP2	6.922	12.5542	1.9182	4.8613
TE-10	CTRP2	6.9478	13.4161	1.5368	6.2437
TE-11	CTRP2	7.041	12.9447	1.8112	5.1195
TE-14	CTRP2	7.1272	8.6559	3.6008	0.0583
COLO 680N	CTRP2	10.4237	28.7566	-3.4501	17.1825

Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
N2a-PK1	CTRP2	5.3483	8.4743	2.8347	3.2683
BxPC-3	CTRP2	0.5938	2.3126	0.576	23.3123
HuP-T4	CTRP2; CTRP1	1.6613	3.4246	1.6383	21.3126
CFPAC-1	CTRP2; CTRP1	3.3395	6.8555	2.5065	13.6861
PaTu 8988s	CTRP2	4.4891	6.4298	3.2318	2.8888
PaTu 8902	CTRP2; CTRP1	4.5012	6.5487	3.8101	6.0381
SNU-410	CTRP2	4.5604	6.8624	3.0717	3.4356
PSN1	CTRP2	4.6076	7.3101	2.8864	4.1249
SUIT-2	CTRP2; CTRP1	4.7928	5.8581	4.4205	3.0453
HPAC	CTRP2; CTRP1	4.9427	6.7661	4.1066	3.9721
KP-4	CTRP2	5.0253	8.476	2.6171	4.5832
SU.86.86	CTRP2	5.0401	8.9631	2.3908	5.4831
Panc 03.27	CTRP2; CTRP1	5.0759	8.7929	3.206	7.2764
Panc 10.05	CTRP2; CTRP1	5.1479	8.4732	3.4253	6.2835
MIA PaCa-2	CTRP2	5.2153	6.9235	3.4625	1.0895
YAPC	CTRP2	5.3319	7.2655	3.3765	1.2746
SW1990	CTRP2	5.4072	9.8345	2.2255	5.6066
PK-45H	CTRP2	5.503	8.2953	3.0135	2.4012
PK-59	CTRP2	5.5419	8.3758	2.9999	2.4079
Panc 04.03	CTRP2	5.5965	9.7775	2.3804	4.7252
Panc 05.04	CTRP2	5.7469	7.6733	3.4161	0.8188
SNU-213	CTRP2	5.9136	7.4307	3.5848	0.3153
KP-2	CTRP2	6.0415	10.2496	2.4426	3.9222
TCC-Pan2	CTRP2	6.1091	7.6149	3.5947	0.2328
Panc 02.03	CTRP2	6.2614	9.0473	3.0993	1.3971
KP-3	CTRP2; CTRP1	6.2735	10.8996	3.0784	5.8631
HuP-T3	CTRP2	6.2937	12.5411	1.5277	7.121
Capan-2	CTRP2; CTRP1	6.335	12.8411	2.1733	9.2146
L3.3	CTRP2	6.3629	12.1066	1.7786	6.0626
Panc 08.13	CTRP2	6.6213	8.2964	3.5454	0.1796
Hs 766T	CTRP2	6.7634	8.3374	3.5824	0.1125
QGP-1	CTRP2; CTRP1	6.8368	10.2085	3.7715	2.619
HPAF-II	CTRP2	7.0981	13.4929	1.5941	5.8515
AsPC-1	CTRP2	7.1736	14.3411	1.2476	7.0387
DAN-G	CTRP2	7.5328	18.7878	-0.6273	13.1446
PaTu 8988t	CTRP2	9.5045	24.3716	-1.9732	14.5607

Cancer Drug Sensitivity Data Curated from 47 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SH4	CTRP2	6.1028	8.9653	3.0527	1.7891
RPMI-7951	CTRP2	2.8013	5.8452	1.9945	11.6301
WM266-4	CTRP2	3.0791	4.2878	2.9265	7.2544
UACC-62	CTRP2	3.3099	4.0507	3.2487	5.388
G-361	CTRP2; CTRP1	3.8829	7.2513	2.876	11.0062
WT2-iPS	CTRP2	4.3113	5.7758	3.4218	2.3922
CJM [Human melanoma]	CTRP2	4.3247	6.0995	3.2716	2.9949
Hs 852.T	CTRP2; CTRP1	4.4892	5.827	4.1366	4.8209
WM88	CTRP2	4.7755	8.1158	2.614	4.9802
A2058	CTRP2	4.9983	13.7877	-0.026	15.1043
Hs 839.T	CTRP2	5.0102	7.7187	2.9713	3.1778
Hs 936.T	CTRP2; CTRP1	5.0465	5.7837	4.6861	1.4927
SK-MEL-30	CTRP2	5.2157	6.754	3.5356	0.8481
WM115	CTRP2	5.2531	8.5347	2.7442	3.7492
UACC-257	CTRP2	5.287	8.4743	2.7951	3.5029
SK-MEL-2	CTRP2	5.3213	6.139	3.8228	0.0883
RVH-421	CTRP2	5.3517	9.1106	2.5353	4.4447
Hs 940.T	CTRP2	5.4028	7.993	3.0914	2.2239
A-375	CTRP2; CTRP1	5.4145	9.1003	3.3263	6.2156
COLO 792	CTRP2	5.4337	12.404	0.9908	10.5063
WM1799	CTRP2	5.464	10.3126	2.0341	6.2937
Hs 688(A).T	CTRP2	5.5565	11.4075	1.5678	8.0259
MDA-MB-435S	CTRP2	5.6362	7.364	3.4894	0.6836
K029AX	CTRP2	5.6733	9.3165	2.6468	3.5879
LOX-IMVI	CTRP2	5.6791	10.0146	2.3223	4.8439
HT-144	CTRP2	5.6809	8.5972	2.9814	2.3248
Mel JuSo	CTRP2	5.7129	7.4457	3.4921	0.6292
IGR-39	CTRP2	5.715	12.1269	1.3302	8.7274
IPC-298	CTRP2	5.7699	7.1656	3.6251	0.289
Hs 294T	CTRP2	5.8607	7.2688	3.6234	0.26
SK-MEL-3	CTRP2	5.912	7.179	3.6757	0.1588
WM793	CTRP2	5.9832	8.2816	3.2803	1.0531
SK-MEL-31	CTRP2	5.9943	10.3156	2.3828	4.2064
SK-MEL-28	CTRP2; CTRP1	6.0766	7.0422	4.7331	0.2585
MeWo	CTRP2	6.1291	10.4944	2.3834	4.0424
SK-MEL-5	CTRP2; CTRP1	6.1392	11.2381	2.8168	7.0594
Hs 895.T	CTRP2	6.2536	7.64	3.64	0.1335
COLO 800	CTRP2	6.3069	8.0829	3.5016	0.3348
IGR-37	CTRP2	6.5175	11.785	2.026	4.9293
IGR-1	CTRP2	6.5316	8.2529	3.5273	0.2253
COLO 741	CTRP1	6.723	10.4242	3.6037	7.4765
SK-MEL-1	CTRP2; CTRP1	6.8511	10.7512	3.5315	3.4467
WM983B	CTRP2	7.2615	9.0672	3.5093	0.1138
Mel Ho	CTRP2	7.5689	15.8014	0.8153	8.1214
Hs 944.T	CTRP2; CTRP1	8.0335	19.3932	0.194	13.6108
A101D	CTRP2	9.1117	25.2163	-2.6398	16.8386
COLO 829	CTRP2	10.7125	23.8934	-0.9904	10.3619

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	CTRP2	6.3523	8.5999	3.324	0.7059

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SiMa	CTRP2	5.2558	7.8538	3.066	2.4906
NH-6	CTRP2	5.3038	10.8156	1.6754	7.9851
SK-N-BE(2)	CTRP2	5.3447	8.9672	2.5991	4.2004
SK-N-DZ	CTRP2	5.6761	7.1639	3.5864	0.4121
SK-N-SH	CTRP2	5.6849	11.854	1.4416	8.3328
NB1	CTRP2	5.7107	8.431	3.0728	1.9663
KP-N-SI9s	CTRP2	6.2769	10.7906	2.3371	4.0438
CHP-126	CTRP2	6.5447	8.8256	3.3203	0.6192
KP-N-YN	CTRP2	6.653	8.2934	3.558	0.1574
Kelly	CTRP2	7.2394	15.4269	0.7802	8.6685
SK-N-FI	CTRP2	8.2305	24.3258	-2.8213	18.4936

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-478	CTRP2	5.0362	7.6588	3.0171	2.9609
HuH-28	CTRP2	5.5046	6.9243	3.6045	0.4549
SNU-1196	CTRP2	5.6139	8.9531	2.7785	3.1563
SNU-869	CTRP2	5.7355	10.404	2.1745	5.3501
HuCC-T1	CTRP2	5.9464	7.3634	3.6227	0.2338
SNU-1079	CTRP2	6.0123	19.6362	-2.1469	20.0967
SNU-308	CTRP2	6.345	12.8785	1.4011	7.539

Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A-673	CTRP2	4.0292	5.4863	3.339	3.2573
SK-N-MC	CTRP2	4.5207	6.9674	2.9907	3.8346
TC71	CTRP2	4.9501	7.8598	2.8628	3.6982
SK-ES-1	CTRP2	5.6523	12.1666	1.2661	9.0761
Hs 822.T	CTRP2	5.7619	6.6727	3.7965	0.0482
SJSA-1	CTRP2	5.808	11.1754	1.8546	6.515
Hs 888.T	CTRP2	6.0568	10.5015	2.3354	4.3113
SaOS-2	CTRP2	6.1251	9.8552	2.6727	2.9735
CAL-78	CTRP2	6.2326	7.8288	3.5652	0.2459
MG-63	CTRP2	6.2391	12.0777	1.7118	6.4827
U2OS	CTRP1	6.8007	12.6464	2.6003	14.508
MHH-ES-1	CTRP2	7.1129	11.2287	2.6115	2.2605
G-292 clone A141B1	CTRP2	7.139	8.8974	3.5239	0.1164
HOS	CTRP2	8.6572	18.458	0.2593	8.7416
SW1353	CTRP2	9.8455	18.554	0.9018	5.4058

Cancer Drug Sensitivity Data Curated from 71 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HCC1954	CTRP2	0.5532	5.5875	-0.2625	26.3771
HCC1569	CTRP2	1.6354	8.258	-0.2779	23.374
Hs 578T	CTRP2	3.408	7.8254	1.626	11.7153
DU4475	CTRP2	3.8786	7.5415	2.1835	8.4059
ZR-75-30	CTRP2	4.4026	7.7027	2.5353	5.9349
MCF-7	CTRP2; CTRP1	5.043	8.6271	3.2615	7.1175
CAL-148	CTRP2	5.0731	12.1223	0.859	11.6267
HCC1428	CTRP2	5.1482	8.3629	2.7561	3.8459
MDA-MB-468	CTRP2	5.2076	9.5905	2.2044	5.9874
HCC1937	CTRP2	5.3232	8.6731	2.7246	3.7325
HCC1419	CTRP2	5.3374	7.6802	3.1949	1.9146
EFM-192A	CTRP2	5.3375	10.1072	2.045	6.4376
BT-20	CTRP2	5.3614	7.8064	3.1518	2.0466
MDA-MB-231	CTRP2	5.3963	8.5378	2.8355	3.2042
HCC202	CTRP2	5.4726	10.5674	1.9167	6.753
Hs 578Bst	CTRP2	5.5016	6.8992	3.613	0.4353
HMC-1-8	CTRP2	5.5592	7.6223	3.3435	1.1839
CAL-85-1	CTRP2	5.6802	10.6526	2.0187	6.044
CAMA-1	CTRP2	5.7074	7.4436	3.4905	0.6368
CAL-120	CTRP2	5.7657	7.086	3.6528	0.2377
BT-474	CTRP2	5.8907	7.2194	3.6532	0.199
ZR-75-1	CTRP2	5.9554	9.1004	2.9133	2.2858
KPL-1	CTRP2	6.0189	11.7235	1.7344	6.6937
MDA-MB-453	CTRP2	6.0809	8.7171	3.147	1.3882
MDA-MB-415	CTRP2	6.1314	9.8697	2.6698	2.9773
HCC38	CTRP2	6.2094	13.9182	0.8086	10.0004
BT-549	CTRP2	6.2362	11.8734	1.8065	6.1197
AU565	CTRP2	6.403	11.0007	2.3169	3.9754
SK-BR-3	CTRP2	6.4523	8.3755	3.4519	0.3783
MDA-MB-361	CTRP2	6.4559	8.2461	3.5008	0.2884
T-47D	CTRP2	6.6717	8.8527	3.3634	0.4718
HCC1395	CTRP2	6.6718	12.6936	1.7001	5.9705
HCC1500	CTRP2	6.7256	15.9519	0.184	11.536
HDQ-P1	CTRP2	6.762	8.3821	3.5666	0.1288
CAL-51	CTRP2	7.0485	12.2401	2.1343	3.9428
HCC1143	CTRP2	7.3588	16.7743	0.2195	10.5156
HCC1806	CTRP2	7.687	16.8653	0.3916	9.4766
JIMT-1	CTRP2	10.6518	25.9136	-1.9606	13.158
BT 498	CTRP2	4.6072	7.2451	2.918	3.995
BT164	CTRP2	4.8231	6.9537	3.2114	2.4789
BT 145	CTRP2	4.8762	7.9858	2.7501	4.2651
BT 231	CTRP2	5.2585	9.6651	2.204	5.9121
BT 112	CTRP2	5.3091	8.5456	2.7758	3.5498
BT 139	CTRP2	5.4787	7.2644	3.4539	0.8978
BT 248	CTRP2	5.6444	9.998	2.3073	4.9495
BT 340	CTRP2	5.6978	7.1718	3.5927	0.3875
BT 131	CTRP2	5.7395	7.0371	3.6604	0.2326
BT 444	CTRP2	5.7901	7.0439	3.6777	0.1875
BT 320	CTRP2	5.8445	6.6932	3.8177	0.0271
BT 286	CTRP2	5.8719	7.6049	3.5008	0.5198
BT 504	CTRP2	5.8957	7.351	3.6071	0.2785
BT 428	CTRP2	5.9064	8.3321	3.2208	1.2937
BT 422	CTRP2	5.9362	7.9017	3.4125	0.7097
BT 271	CTRP2	5.958	7.7836	3.4689	0.5535
BT 333	CTRP2	6.0324	7.2234	3.7043	0.0984
BT 330	CTRP2	6.0496	7.4447	3.6331	0.188
BT 228	CTRP2	6.1014	7.4362	3.6555	0.1443
BT 328	CTRP2	6.1128	7.1532	3.756	0.0434
BT 482	CTRP2	6.1316	7.3862	3.6838	0.1045
BT 440	CTRP2	6.2641	7.6512	3.6399	0.1316
BT 216	CTRP2	6.3217	7.8624	3.5871	0.189
BT 172	CTRP2	6.3558	7.5112	3.7195	0.0465
BT147	CTRP2	6.3581	8.0841	3.5214	0.2827
BT 159	CTRP2	6.4229	7.8371	3.6328	0.1123
BT 359	CTRP2	6.4803	8.0607	3.5761	0.1689
BT 239	CTRP2	6.5083	7.6931	3.7107	0.0401
BT 245	CTRP2	6.5489	8.0345	3.61	0.1166
BT 232	CTRP2	6.6423	8.0057	3.6523	0.0667
BT 187	CTRP2	6.7161	8.7158	3.4317	0.3281
BT 179	CTRP2	6.8222	12.1094	2.0614	4.448
BT 224	CTRP2	7.0936	11.707	2.3952	2.9911

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	4.6838	6.2265	3.4647	1.664

Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ONS-76	CTRP2	2.3343	4.8363	1.9279	13.1409
CAS-1	CTRP2	2.5969	5.4708	1.9499	12.3371
GaMG	CTRP2; CTRP1	3.7449	6.8209	2.9358	11.1034
SF295	CTRP2; CTRP1	4.0735	7.4887	2.9495	10.2947
GB-1	CTRP2	4.2247	7.8533	2.3176	7.1705
SF539	CTRP2	4.2915	9.5361	1.5313	10.3203
Hs 683	CTRP2	4.6353	6.4028	3.3484	2.1926
Daoy	CTRP2	4.6553	10.1912	1.4949	9.8056
SW1088	CTRP2	4.7756	11.2598	1.0574	11.3622
T98G	CTRP2	4.9578	9.552	2.0423	7.042
KNS-81	CTRP2	4.9635	7.9208	2.8426	3.76
LN-18	CTRP2	4.9754	6.5281	3.5036	1.178
LN-229	CTRP2; CTRP1	5.0693	9.5646	2.8147	8.8278
KALS-1	CTRP2	5.0843	7.5505	3.0995	2.5742
GMS-10	CTRP2	5.093	6.7603	3.4668	1.1902
U-87MG ATCC	CTRP2	5.124	10.5787	1.66	8.3354
SF126	CTRP2	5.2366	10.1504	1.9522	6.9681
A-172	CTRP2	5.2953	8.1429	2.9562	2.8638
GOS-3	CTRP2	5.314	7.7725	3.139	2.147
U-118MG	CTRP2	5.3298	7.7936	3.1388	2.1298
SW1783	CTRP2	5.345	7.5252	3.269	1.6385
M059K	CTRP2	5.361	8.4165	2.8699	3.1154
CCF-STTG1	CTRP2	5.3899	7.5567	3.2804	1.5528
SF268	CTRP2	5.3944	12.0683	1.1269	10.0347
SNU-466	CTRP2	5.4254	8.1948	3.0127	2.4923
D283 Med	CTRP2	5.5044	7.5051	3.365	1.1599
SNU-738	CTRP2	5.5867	7.2696	3.5043	0.6733
KG-1-C	CTRP2	5.624	6.8587	3.68	0.2353
DK-MG	CTRP2	5.6457	7.2588	3.5359	0.5526
SNU-626	CTRP2	5.8378	7.1705	3.6503	0.2193
SNU-1105	CTRP2	5.8747	6.9465	3.7431	0.0822
YH-13	CTRP2	5.9511	9.8767	2.5592	3.5885
U-251MG	CTRP2	6.0441	10.1443	2.4927	3.73
KNS-60	CTRP2	6.0942	12.864	1.2381	8.5232
SNU-489	CTRP2	6.1475	7.4153	3.6794	0.1066
8-MG-BA	CTRP2	6.2171	11.7033	1.8745	5.8821
SNB-75	CTRP2	6.4509	15.3013	0.3072	11.4999
42-MG-BA	CTRP2	6.5414	7.9943	3.6211	0.1063
DBTRG-05MG	CTRP2	6.9291	8.8676	3.4585	0.2298
Becker	CTRP2	7.1549	13.2261	1.7508	5.2115
SNU-201	CTRP2	7.7881	20.6418	-1.3454	15.0348

Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HEC-265	CTRP1	1.0551	2.4383	1.0529	57.1317
HEC-151	CTRP2; CTRP1	4.2372	7.513	3.0942	9.3778
HEC-1-A	CTRP2	4.5368	9.4579	1.7669	8.8973
JHUEM-7	CTRP2	4.7145	7.26	2.9886	3.5367
HEC-6	CTRP2; CTRP1	5.0686	6.2866	4.4531	2.3718
HEC-50B	CTRP2	5.0696	7.6457	3.0452	2.8058
JHUEM-1	CTRP2	5.1512	8.1322	2.8681	3.3958
EFE-184	CTRP2	5.1803	8.8805	2.5292	4.7116
HEC-59	CTRP2; CTRP1	5.676	7.9062	4.111	2.758
ESS-1	CTRP2	5.6898	10.1994	2.2416	5.1475
AN3-CA	CTRP2	5.7434	10.5093	2.1296	5.5165
MFE-319	CTRP2; CTRP1	6.1636	11.3125	2.7981	7.0945
HEC-1-B	CTRP2	6.2726	11.85	1.8411	5.9386
MFE-296	CTRP2	6.302	12.4195	1.591	6.8653
KLE	CTRP2; CTRP1	6.33	16.6215	0.2998	15.8669
EN	CTRP2	6.3932	11.1706	2.2331	4.2983
JHUEM-3	CTRP2	6.6582	8.6384	3.4371	0.3365
HEC-108	CTRP2; CTRP1	6.9513	12.8692	2.596	6.7523
RL95-2	CTRP2	7.294	14.8569	1.0828	7.4942
HEC-251	CTRP2; CTRP1	7.3277	14.5844	2.0286	8.3326
JHUEM-2	CTRP2; CTRP1	9.1663	32.9633	-5.6356	25.4713
Ishikawa (Heraklio) 02 ER-	CTRP2; CTRP1	5.1119	8.5766	3.344	6.668

Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
UO-31	CTRP2	2.8511	6.8321	1.5855	13.1559
BFTC-909	CTRP2	3.7858	7.8921	1.9283	9.6614
786-O	CTRP2	4.2734	8.8005	1.8841	8.8918
RCC10RGB	CTRP2; CTRP1	4.7599	6.318	4.1656	4.1052
VMRC-RCZ	CTRP2	4.9674	8.3958	2.6153	4.6772
Caki-2	CTRP2	5.3	8.0323	3.0107	2.6488
A-498	CTRP2	5.3778	7.0252	3.5035	0.8212
KMRC-20	CTRP2	5.4234	8.4169	2.9089	2.8882
KMRC-2	CTRP2	5.4898	8.8754	2.7368	3.4689
TUHR14TKB	CTRP2	5.5102	14.8727	-0.1702	14.7252
SNU-1272	CTRP2	5.6127	9.5008	2.5219	4.1482
TUHR10TKB	CTRP2	5.8311	8.1749	3.2488	1.2651
KMRC-1	CTRP2	6.0281	10.5612	2.2896	4.5218
ACHN	CTRP2	6.0641	10.2638	2.4499	3.8682
OS-RC-2	CTRP2	6.1837	7.8758	3.5287	0.3264
TUHR4TKB	CTRP2	6.2239	7.5741	3.6521	0.1246
KMRC-3	CTRP2	6.4411	8.1905	3.5152	0.2687
Caki-1	CTRP2	6.7711	11.5133	2.3008	3.636
VMRC-RCW	CTRP2; CTRP1	6.8836	13.8138	2.0931	8.7081
769-P	CTRP2	7.0678	16.0561	0.3677	10.3901

Cancer Drug Sensitivity Data Curated from 52 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LS513	CTRP2; CTRP1	1.3736	4.546	1.1646	23.7137
SNU-C4	CTRP2; CTRP1	2.3662	5.118	2.104	17.6957
SNU-C5	CTRP2; CTRP1	2.8533	6.5061	2.1455	16.2317
SNU-61	CTRP2; CTRP1	2.8668	15.053	-1.865	28.7929
SNU-407	CTRP2	2.9291	6.5295	1.8045	12.0796
SW480	CTRP1	3.1626	8.139	1.7501	35.4963
COLO 320	CTRP2; CTRP1	3.3568	8.2309	1.3792	12.8415
CL-34	CTRP1	3.5665	6.5275	2.8829	26.4949
CL-11	CTRP2	3.6236	6.7027	2.3757	8.1355
NCI-H747	CTRP2	3.7251	7.1579	2.2408	8.4822
SK-CO-1	CTRP2; CTRP1	3.7779	7.1487	2.8195	11.4634
C2BBe1	CTRP2; CTRP1	3.8483	6.2729	3.284	9.555
CW-2	CTRP1	3.9332	9.6828	1.7528	31.0461
KM12	CTRP2; CTRP1	4.0651	6.5364	3.3875	8.6451
SW48	CTRP2; CTRP1	4.2443	8.3971	2.6703	11.0046
CL-40	CTRP1	4.2937	6.739	3.5192	17.3491
SNU-C1	CTRP2	4.3846	6.1984	3.2682	2.9082
GP2d	CTRP2; CTRP1	4.3889	8.0412	2.9782	9.5057
SW1116	CTRP2	4.4098	28.1709	-7.6867	33.2313
LS180	CTRP2; CTRP1	4.553	5.9819	4.1292	4.6993
SW948	CTRP2; CTRP1	4.7316	8.4206	3.0981	8.3471
RCM-1 [Human ESC]	CTRP2; CTRP1	4.8285	7.1781	3.8017	5.3925
SNU-503	CTRP2	4.8866	9.6546	1.9386	7.5853
HCC-56	CTRP2	4.9855	10.4716	1.6094	8.7697
SNU-175	CTRP1	4.9948	11.5042	1.7826	25.9085
SW620	CTRP2; CTRP1	5.069	10.2828	2.4554	10.2333
OUMS-23	CTRP2	5.0833	7.1433	3.2881	1.8527
HCT 15	CTRP2	5.1533	8.2347	2.8207	3.5811
COLO201	CTRP2	5.3044	9.9935	2.0769	6.3583
SNU-81	CTRP2; CTRP1	5.3391	10.7895	2.4236	9.8757
COLO205	CTRP2; CTRP1	5.3459	8.9075	3.3682	6.1662
DLD-1	CTRP2; CTRP1	5.3657	7.1926	4.2357	2.7318
LS411N	CTRP2; CTRP1	5.369	8.6754	3.5021	5.6011
CCK-81	CTRP2	5.3803	11.0582	1.612	8.1207
HT-29	CTRP2; CTRP1	5.4073	9.2263	3.258	6.4959
MDST8	CTRP2; CTRP1	5.4814	9.1388	3.3594	5.9753
HT115	CTRP2; CTRP1	5.4913	9.293	3.2905	6.2295
NCI-H508	CTRP2; CTRP1	5.8007	12.8125	1.7816	11.539
SW1417	CTRP2	5.8261	9.1743	2.8054	2.8118
NCI-H716	CTRP2	6.0027	12.5852	1.3095	8.3793
COLO 678	CTRP2; CTRP1	6.0674	11.1898	2.7879	7.278
SNU-1040	CTRP1	6.1498	12.6876	2.1112	19.6675
HCT 116	CTRP2; CTRP1	6.4534	11.4056	2.9591	6.0651
T84	CTRP2	6.5771	8.4526	3.473	0.2994
SNU-1033	CTRP2	6.8083	8.9079	3.3978	0.3586
SNU-C2A	CTRP2; CTRP1	7.1779	17.8582	0.3279	14.4329
HT-55	CTRP2; CTRP1	7.3558	14.8447	1.9226	8.6777
HCT 8	CTRP2; CTRP1	7.3796	8.6195	4.6631	0.0573
SW403	CTRP1	7.6007	14.248	2.3707	13.7007
RKO	CTRP2; CTRP1	7.7426	13.2766	2.9128	4.6519
LS123	CTRP2; CTRP1	7.9673	16.2773	1.6491	8.8448
LoVo	CTRP2; CTRP1	8.2857	16.5028	1.7508	8.0938

Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Li-7	CTRP2	0.3867	4.8986	-0.1987	26.6631
HuH-6	CTRP2	1.9226	5.0432	1.4091	16.2699
SNU-761	CTRP2	3.8523	8.5054	1.6796	10.5611
SNU-886	CTRP2	4.0986	9.0126	1.6342	10.2626
JHH-5	CTRP2	4.107	8.859	1.7179	9.899
SNU-182	CTRP2	4.2587	11.4017	0.572	14.2346
Hep-G2	CTRP2; CTRP1	4.6711	7.521	3.4914	6.9226
JHH-4	CTRP2	5.0417	9.358	2.1989	6.2653
JHH-2	CTRP2	5.0506	10.1264	1.8282	7.7687
SNU-475	CTRP2	5.2021	9.1109	2.4331	5.0681
SNU-449	CTRP2; CTRP1	5.3012	8.3989	3.5863	5.3841
HuH-1	CTRP2	5.3983	10.2903	1.9989	6.5327
SNU-878	CTRP2	5.5487	10.3279	2.0851	5.9661
Hep 3B2.1-7	CTRP2	5.5576	9.7947	2.3465	4.9122
SNU-387	CTRP2	5.8541	8.9675	2.915	2.3826
JHH-1	CTRP2	5.8969	10.7179	2.1318	5.3017
SNU-423	CTRP2	5.9307	11.9725	1.5552	7.5214
HLF	CTRP2	6.0088	8.3681	3.257	1.1043
JHH-6	CTRP2; CTRP1	6.2222	7.5639	4.5918	0.5296
SNU-398	CTRP1	6.8863	12.5172	2.7208	13.4527
SK-HEP-1	CTRP2	7.6831	17.8308	-0.0681	11.0726

Cancer Drug Sensitivity Data Curated from 155 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H82	CTRP1	-1.742	7.6816	-3.2144	67.5067
SCLC-21H	CTRP1	-0.0757	3.0363	-0.1492	69.0802
NCI-H810	CTRP2; CTRP1	0.7724	2.8405	0.7528	26.8583
LCLC-97TM1	CTRP2; CTRP1	1.9799	4.0286	1.9136	19.4591
NCI-H2106	CTRP2	2.054	6.7702	0.8218	18.1817
Calu-3	CTRP2; CTRP1	2.0662	6.5264	1.301	21.3038
NCI-H1666	CTRP2; CTRP1	2.0934	6.606	1.2993	21.237
COR-L279	CTRP1	2.3728	6.5695	1.611	41.6392
SBC-5	CTRP2	2.5235	5.6247	1.8078	13.0891
NCI-H211	CTRP2	2.6274	8.82	0.4163	18.3318
HCC44	CTRP2; CTRP1	2.769	7.3358	1.7099	18.0251
COR-L51	CTRP1	2.9869	7.7338	1.7576	36.6106
NCI-H1568	CTRP2; CTRP1	2.9929	6.9885	2.091	16.0755
NCI-H1048	CTRP1	3.0296	7.7971	1.7724	36.2637
NCI-H1581	CTRP2	3.1025	8.1921	1.1658	14.2742
NCI-H1155	CTRP2	3.1538	19.0697	-4.1952	30.1834
DMS 273	CTRP2; CTRP1	3.1943	6.3927	2.5512	13.8862
NCI-H1105	CTRP1	3.2366	25.9637	-6.9484	45.9918
EBC-1	CTRP2; CTRP1	3.336	5.9119	2.8923	12.2879
NCI-H1944	CTRP2; CTRP1	3.3666	7.5273	2.2344	14.6331
NCI-H2087	CTRP2	3.4759	9.8971	0.6585	15.4841
NCI-H1437	CTRP1	3.5101	8.308	2.014	32.1362
HCC78	CTRP2; CTRP1	3.6711	6.4698	3.0158	10.9845
CAL-12T	CTRP2; CTRP1	3.7021	6.9518	2.8335	11.5894
A-549	CTRP2; CTRP1	3.7476	6.5328	3.0669	10.6075
RERF-LC-KJ	CTRP1	3.9006	7.4997	2.7766	25.2725
HARA [Human squamous cell lung carcinoma]	CTRP2; CTRP1	3.918	7.1763	2.9455	10.6611
NCI-H2122	CTRP2; CTRP1	4.0117	7.1009	3.073	9.9613
Lu-99	CTRP2; CTRP1	4.089	7.9585	2.7385	11.0727
NCI-H2073	CTRP1	4.09	9.6531	1.9116	29.4548
NCI-H1963	CTRP1	4.0943	7.1348	3.1378	21.5186
KNS-62	CTRP2; CTRP1	4.1582	6.5004	3.4971	8.0124
COLO 668	CTRP2; CTRP1	4.2597	7.8173	2.9678	9.8186
NCI-H1930	CTRP1	4.3045	7.6509	3.0908	20.7708
COLO 699	CTRP2; CTRP1	4.306	22.5974	-4.3454	30.7446
DMS 53	CTRP2	4.3959	8.0511	2.3565	6.6944
HCC366	CTRP2	4.4544	8.79	2.0346	7.9333
NCI-H2029	CTRP2; CTRP1	4.4787	9.096	2.5385	11.0359
SK-MES-1	CTRP2	4.4849	6.8942	3	3.8553
HCC4006	CTRP2; CTRP1	4.507	10.2186	2.0059	13.0376
NCI-H596	CTRP1	4.5151	9.2957	2.4719	24.1113
HCC1588	CTRP2	4.5702	5.937	3.5275	1.5675
PC-14	CTRP2	4.6051	8.6482	2.2228	6.8844
NCI-H2081	CTRP2; CTRP1	4.6516	7.0274	3.7175	6.0778
DMS 454	CTRP2	4.6928	10.3695	1.4355	9.982
NCI-H526	CTRP2	4.7032	6.4017	3.3945	1.9148
VMRC-LCD	CTRP2; CTRP1	4.7049	8.1762	3.1963	8.0135
NCI-H446	CTRP2	4.7751	9.5869	1.8877	7.9822
LXF 289	CTRP2; CTRP1	4.7761	9.045	2.8255	9.3311
NCI-H1792	CTRP2; CTRP1	4.7823	8.0268	3.3386	7.3033
NCI-H1975	CTRP1	4.7979	9.6731	2.5309	22.4031
NCI-H647	CTRP2	4.8051	8.0299	2.6776	4.6714
SHP-77	CTRP2; CTRP1	4.8827	12.0971	1.3919	14.6208
NCI-H2444	CTRP2	4.8829	7.7501	2.8692	3.7704
NCI-H23	CTRP2; CTRP1	4.8944	8.4394	3.2297	7.5178
COR-L95	CTRP2	4.9059	10.5225	1.5239	9.252
HOP-62	CTRP2	4.9142	8.9334	2.3142	5.9941
Lu-65	CTRP2; CTRP1	4.9805	9.1622	2.9416	8.4914
HCC2108	CTRP2; CTRP1	4.9943	11.7094	1.6797	13.3422
LK2	CTRP2	5.018	6.6873	3.4567	1.3027
NCI-H2196	CTRP2	5.0187	9.732	1.9986	7.1227
NCI-H1341	CTRP2	5.0242	9.6769	2.0298	6.9862
EKVX	CTRP2	5.0398	23.0777	-4.6262	27.5017
NCI-H1734	CTRP2	5.0426	7.2476	3.2148	2.1805
HCC33	CTRP1	5.0658	11.2619	1.9631	24.6482
NCI-H1092	CTRP2	5.1087	8.0999	2.8553	3.5047
NCI-H322	CTRP2	5.114	6.925	3.4053	1.3876
NCI-H520	CTRP2	5.1351	8.1082	2.8689	3.4145
NCI-H1703	CTRP2	5.1394	10.033	1.9393	7.1728
EPLC-272H	CTRP2; CTRP1	5.1466	8.0843	3.6186	5.524
NCI-H2009	CTRP2; CTRP1	5.15	10.337	2.4954	9.9311
NCI-H1563	CTRP2	5.1705	8.8577	2.5335	4.7087
NCI-H1373	CTRP2; CTRP1	5.1878	8.3874	3.5008	5.9161
ChaGo-K-1	CTRP2; CTRP1	5.2329	9.3137	3.0747	7.5146
NCI-H1836	CTRP1	5.2732	8.4427	3.5421	12.6712
Calu-6	CTRP2; CTRP1	5.2754	9.0826	3.2244	6.852
MOR/CPR	CTRP2	5.3405	6.1029	3.8423	0.0616
SW1271	CTRP2	5.3421	10.344	1.9331	6.8834
NCI-H2291	CTRP2	5.365	10.0677	2.0835	6.2406
HCC1171	CTRP2	5.3651	16.9054	-1.2903	18.702
NCI-H2126	CTRP2; CTRP1	5.3687	7.9049	3.8851	4.098
NCI-H2110	CTRP2; CTRP1	5.406	10.2875	2.7279	8.5754
NCI-H226	CTRP2	5.4071	9.854	2.2161	5.6446
COR-L23	CTRP1	5.427	7.2809	4.2378	6.0079
BEN	CTRP2; CTRP1	5.4398	10.6028	2.5976	9.0261
RERF-LC-Ad1	CTRP2	5.5004	6.3955	3.7988	0.0832
NCI-H2170	CTRP2	5.5086	8.6292	2.8634	2.9593
NCI-H1435	CTRP2; CTRP1	5.5714	10.0197	2.9916	7.2679
NCI-H196	CTRP2	5.5837	9.7836	2.3691	4.7872
HCC1359	CTRP1	5.5904	8.0876	3.9614	7.8762
NCI-H2141	CTRP1	5.6049	7.7932	4.1157	6.4828
NCI-H1339	CTRP2	5.6171	8.273	3.0901	1.9994
NCI-H838	CTRP2	5.6368	9.787	2.4024	4.5851
LUDLU-1	CTRP2	5.6641	11.5731	1.5633	7.881
NCI-H889	CTRP2	5.6951	9.3615	2.6395	3.5892
NCI-H3255	CTRP1	5.6972	10.7302	2.736	17.2938
NCI-H1876	CTRP1	5.7063	13.7639	1.2334	25.7564
LC-1/sq-SF	CTRP2; CTRP1	5.7177	9.039	3.5876	4.7132
NCI-H2228	CTRP2	5.7478	12.1925	1.3215	8.7118
RERF-LC-MS	CTRP2	5.8279	10.8931	2.003	5.9008
RERF-LC-Ad2	CTRP2	5.8646	9.2975	2.7722	2.8919
IA-LM	CTRP2	5.8656	8.5883	3.0892	1.7616
HCC2935	CTRP2; CTRP1	5.8869	10.2646	3.1097	6.3098
SW1573	CTRP2	5.8997	9.3378	2.7746	2.8442
NCI-H1781	CTRP1	5.918	8.0725	4.1938	4.8716
NCI-H460	CTRP2; CTRP1	5.9342	8.6282	3.9405	3.0551
LCLC-103H	CTRP2; CTRP1	5.9411	9.872	3.3421	5.3301
HCC1438	CTRP2	5.9665	10.1985	2.4198	4.0988
NCI-H1793	CTRP2; CTRP1	5.9747	9.7216	3.4397	4.9059
NCI-H1299	CTRP2; CTRP1	5.9834	11.0849	2.7774	7.4467
NCI-H292	CTRP2	6.0997	14.546	0.4256	11.6018
HOP-92	CTRP2	6.2227	11.025	2.1956	4.6422
NCI-H2023	CTRP2; CTRP1	6.2456	11.1592	2.9323	6.4608
DMS 114	CTRP2	6.261	9.0501	3.0979	1.4017
HCC1195	CTRP2; CTRP1	6.2739	10.5276	3.2589	5.1757
NCI-H727	CTRP2; CTRP1	6.3082	12.3715	2.3843	8.4575
NCI-H1623	CTRP2	6.3405	11.7585	1.9276	5.5195
NCI-H358	CTRP2; CTRP1	6.3477	11.3182	2.9274	6.3335
COR-L88	CTRP1	6.3676	9.1519	3.9729	5.4872
Calu-1	CTRP2	6.5111	8.0955	3.5752	0.1637
COR-L105	CTRP2	6.5137	9.1367	3.1842	0.9784
NCI-H1651	CTRP2	6.5478	8.4601	3.4588	0.3332
NCI-H1184	CTRP2	6.5713	8.6881	3.3838	0.4691
NCI-H1355	CTRP2; CTRP1	6.6131	12.0124	2.7767	6.5336
HCC827	CTRP2; CTRP1	6.6454	12.1807	2.7178	6.7109
NCI-H1573	CTRP2; CTRP1	6.8217	8.734	4.4	0.6743
NCI-H522	CTRP2; CTRP1	6.8717	11.2014	3.3349	4.1306
NCI-H1915	CTRP2; CTRP1	6.9563	11.4347	3.2794	4.2324
SK-LU-1	CTRP2; CTRP1	6.9653	13.1912	2.451	7.2712
NCI-H650	CTRP2; CTRP1	7.026	12.7393	2.7084	6.2385
T3M-10	CTRP2; CTRP1	7.045	12.9291	2.6306	6.5014
Sq-1	CTRP2; CTRP1	7.0489	12.6734	2.7551	6.0374
NCI-H1869	CTRP2	7.1162	15.5516	0.6405	9.3399
NCI-H1395	CTRP2	7.1398	9.4765	3.3206	0.3903
NCI-H2085	CTRP2	7.1805	35.6937	-9.2178	31.0828
NCI-H1755	CTRP2; CTRP1	7.205	13.9767	2.2369	7.7382
NCI-H2286	CTRP2; CTRP1	7.2851	13.4371	2.5482	6.4961
DV-90	CTRP2; CTRP1	7.3078	9.12	4.4606	0.3268
NCI-H2342	CTRP2; CTRP1	7.3694	13.9865	2.3427	7.1372
NCI-H2172	CTRP2; CTRP1	7.4008	13.2197	2.7261	5.7072
HCC15	CTRP2; CTRP1	7.4548	11.6823	3.4665	3.0422
NCI-H841	CTRP2; CTRP1	7.4889	18.5001	0.2401	14.2491
NCI-H661	CTRP2; CTRP1	7.5483	13.4296	2.7216	5.5481
NCI-H2405	CTRP2; CTRP1	7.588	12.7824	3.046	4.3534
HCC95	CTRP2	7.6427	19.5793	-0.9331	13.9695
NCI-H1838	CTRP2	7.6768	25.3109	-3.7018	21.3946
NCI-H1650	CTRP2	7.8062	15.593	1.0592	6.963
HCC1833	CTRP2; CTRP1	8.0328	17.3013	1.2037	10.2962
NCI-H1694	CTRP2; CTRP1	8.2315	20.7337	-0.3177	14.8999
NCI-H2030	CTRP2; CTRP1	8.5485	16.2673	2.0271	6.8337
HCC2279	CTRP2	9.1332	21.7022	-0.9537	12.0644
RERF-LC-A1	CTRP2	9.5844	30.2815	-4.7594	21.0719
LOU-NH91	CTRP2	9.8204	22.1295	-0.7214	10.5421
NCI-H441	CTRP2; CTRP1	10.615	20.6639	1.2561	7.174
Hs 888.Lu	CTRP2	6.1891	8.1909	3.4117	0.5756

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Thigh Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
H-STS	CTRP2	3.7701	8.7779	1.4728	11.5835
SYO-1	CTRP2	6.7975	8.5249	3.5301	0.164

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Yamato-SS	CTRP2	4.7562	11.1226	1.1105	11.1841
Aska-SS	CTRP2	5.1937	7.1861	3.3341	1.5612
A-204	CTRP2	3.8581	8.2334	1.8204	9.9638
G-401	CTRP2; CTRP1	4.99	10.8471	2.1072	11.7253
TE 617.T	CTRP2	5.0981	8.419	2.6951	4.1612
BT-12	CTRP2	5.1081	5.9501	3.8087	0.1719
TE 441.T	CTRP2	5.2301	7.9674	2.997	2.7877
SK-LMS-1	CTRP2	5.2502	8.1785	2.9108	3.0974
RKN	CTRP2; CTRP1	5.3656	7.0435	4.3092	2.4458
GCT	CTRP2	5.5648	9.9163	2.2933	5.1135
G-402	CTRP2	5.708	11.6019	1.5801	7.7487
SK-UT-1	CTRP2	5.792	9.3026	2.7264	3.1444
SW982	CTRP2	5.7951	6.9438	3.7152	0.1302
Rh18	CTRP2	5.9947	8.4076	3.2336	1.1855
RD	CTRP2	6.0065	9.692	2.677	3.0863
BT-16	CTRP2	6.3158	7.5832	3.6816	0.0798
Rh41	CTRP2	6.3894	13.6854	1.0449	8.841
KYM-1	CTRP2	6.429	13.4983	1.1614	8.3417
Hs 729.T	CTRP2	6.4327	12.4424	1.6655	6.406
Tm87-16	CTRP2	6.462	7.782	3.6653	0.0761
TTC-709	CTRP2	6.5953	7.9267	3.6626	0.0638
MES-SA	CTRP2	6.7143	13.1572	1.5103	6.6341
HT-1080	CTRP2; CTRP1	6.8802	12.2067	2.8652	5.8468

Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
2004	CTRP2	6.4985	8.7542	3.328	0.6234
COV434	CTRP2; CTRP1	1.5034	5.7872	0.9579	24.0307
A2780	CTRP2; CTRP1	2.534	6.8802	1.6569	18.8138
TYK-nu	CTRP2; CTRP1	3.2902	7.8973	1.9886	15.7322
OVK18	CTRP2; CTRP1	4.2275	9.3178	2.2023	12.8485
RMUG-S	CTRP1	4.4182	10.8954	1.5909	29.4066
RMG-I	CTRP2; CTRP1	4.5132	10.4456	1.8983	13.4361
SNU-119	CTRP2	4.6139	11.2674	0.9262	12.1759
MCAS	CTRP2	4.7615	8.4431	2.4426	5.7103
ES2	CTRP2	4.7742	9.8051	1.7788	8.4327
OVCAR-4	CTRP2; CTRP1	4.796	9.7507	2.4905	10.6038
JHOS-4	CTRP1	4.9474	10.7844	2.1027	24.371
OVCAR-8	CTRP2; CTRP1	5.0575	7.8442	3.665	5.5002
HEY A8	CTRP2; CTRP1	5.1952	10.7107	2.3458	10.4314
JHOC-5	CTRP2; CTRP1	5.237	6.9423	4.2612	2.838
OV56	CTRP2	5.2485	8.2361	2.8826	3.2099
TOV-112D	CTRP2	5.2905	9.7408	2.1898	5.9221
ONCO-DG-1	CTRP2	5.4094	9.8675	2.2112	5.6612
DOV13	CTRP2	5.4126	13.9354	0.2195	13.4815
OVMANA	CTRP1	5.4248	12.8559	1.461	25.7604
OV-90	CTRP2; CTRP1	5.61	10.9984	2.535	8.9826
IGROV-1	CTRP2; CTRP1	5.7353	8.9001	3.6687	4.3731
OVCAR-5	CTRP2	5.764	8.5978	3.0287	2.0688
OVISE	CTRP2	5.7934	8.8584	2.929	2.3955
SNU-8	CTRP2	5.8508	7.0108	3.7122	0.1224
OVSAHO	CTRP2	5.8738	9.8713	2.514	3.8517
COV644	CTRP2; CTRP1	5.9176	8.6456	3.9209	3.151
OAW28	CTRP2	6.0217	12.3237	1.4486	7.8087
FU-OV-1	CTRP2	6.0815	8.1008	3.3994	0.6614
OVKATE	CTRP1	6.1207	11.089	2.8765	14.7869
JHOS-2	CTRP2	6.1246	7.8916	3.4987	0.409
Kuramochi	CTRP2	6.1795	15.5301	0.0021	13.0151
OVTOKO	CTRP2	6.393	9.037	3.1679	1.0998
COV362	CTRP2; CTRP1	6.4023	9.759	3.7119	3.3154
COV318	CTRP1	6.4609	9.2268	3.995	5.0824
OAW42	CTRP2; CTRP1	6.4737	7.5754	4.6966	0.1812
JHOM-1	CTRP1	6.6899	14.7224	1.5098	21.1305
OC 314	CTRP2	6.8956	12.2613	2.0359	4.4603
SK-OV-3	CTRP2; CTRP1	6.9183	11.0101	3.4532	3.6508
EFO-27	CTRP2; CTRP1	7.107	11.0918	3.5301	3.175
EFO-21	CTRP2; CTRP1	7.2897	11.6398	3.3893	3.4731
Caov-3	CTRP2; CTRP1	8.408	17.0868	1.5545	8.6193
OV7	CTRP2; CTRP1	12.6407	26.139	-0.0341	8.9934
SNU-840	CTRP2; CTRP1	13.0085	27.8104	-0.5733	10.0964

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MSTO-211H	CTRP2; CTRP1	2.6901	6.0226	2.1588	16.6129
NCI-H28	CTRP2; CTRP1	3.7195	7.7039	2.5033	12.7972
NCI-H2452	CTRP2	5.5573	12.0212	1.2688	9.2135
JL-1	CTRP2	5.9718	8.1313	3.3365	0.8972
NCI-H2052	CTRP1	7.3302	13.1781	2.7002	12.3414
IST-Mes1	CTRP2	9.6444	22.3296	-0.9232	11.3574
ACC-MESO-1	CTRP2	9.8932	28.8105	-3.8341	18.7119

Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LNCaP clone FGC	CTRP2	4.5712	8.9476	2.0478	7.6711
DU145	CTRP2	5.0637	9.9379	1.9306	7.3291
VCaP	CTRP2	5.2616	8.203	2.9066	3.0992
22Rv1	CTRP2	5.8745	13.658	0.6974	10.9337
PaCa-3	CTRP2; CTRP1	5.8861	9.1558	3.6522	4.2172

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-15	CTRP2	5.0125	7.4568	3.0973	2.6761
A-253	CTRP2	5.147	8.5643	2.6587	4.2378

Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
GSS	CTRP2	0.8294	2.558	0.8048	21.7675
Fu97	CTRP1	1.2676	2.4152	1.2669	54.147
SNU-620	CTRP2	1.9726	8.9206	-0.258	22.4296
ECC10	CTRP2	2.8429	5.0991	2.3633	10.0642
AGS	CTRP2; CTRP1	2.9578	6.0149	2.4488	14.8704
SNU-16	CTRP2	3.1974	6.322	2.163	9.9785
HGC-27	CTRP2	3.5322	7.7037	1.7981	10.7348
SNU-1	CTRP2	4.2142	7.9849	2.2434	7.5013
GSU	CTRP2	4.6061	6.0138	3.5146	1.57
HuG1-N	CTRP2	4.9052	9.539	2.0095	7.2626
MKN1	CTRP2	5.0238	8.5986	2.5566	4.8314
NUGC-4	CTRP2; CTRP1	5.028	9.5055	2.8098	8.9222
Hs 746.T	CTRP2	5.0947	7.7704	3.0025	2.9404
MKN74	CTRP2; CTRP1	5.204	10.5623	2.4272	10.1
SNU-5	CTRP2	5.2126	8.9659	2.5103	4.7411
ECC12	CTRP2	5.3144	10.0408	2.061	6.4077
IM95	CTRP2	5.4843	9.2061	2.5777	4.0976
23132/87	CTRP2	5.5563	7.1481	3.5391	0.5964
KE-39	CTRP2	5.6094	9.9677	2.2985	5.0317
MKN45	CTRP2	5.7798	6.6672	3.8045	0.0404
NUGC-3	CTRP2	5.9048	9.5022	2.7029	3.1036
SH-10-TC	CTRP2; CTRP1	5.9264	9.8747	3.3301	5.3983
SNU-668	CTRP2	6.1007	9.9342	2.6226	3.1829
NCC-StC-K140	CTRP2	6.2339	11.9415	1.7729	6.253
SNU-216	CTRP2	6.2739	14.8253	0.4136	11.3783
SNU-601	CTRP2	6.6211	8.1013	3.6127	0.1031
SNU-719	CTRP2	6.6928	8.9098	3.3506	0.4895
MKN7	CTRP2; CTRP1	6.9883	13.8526	2.1476	8.3604
NCI-N87	CTRP2	7.1567	9.4172	3.3486	0.3382
LMSU	CTRP2	7.5862	14.8828	1.252	6.528
SNU-1077	CTRP2	3.9855	7.194	2.4484	7.0816
SNU-685	CTRP2	5.4959	8.4262	2.9492	2.6494
SNG-M	CTRP2; CTRP1	5.6091	9.6787	3.19	6.4315

Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
B-CPAP	CTRP2	1.1388	2.3728	1.1329	19.6453
SW579	CTRP2	4.0094	5.7784	3.176	3.9806
ML-1 [Human leukemia]	CTRP2	4.6043	6.1391	3.4538	1.8137
CGTH-W-1	CTRP2	5.0999	9.0619	2.3852	5.4148
TT	CTRP2	5.6294	7.3279	3.5008	0.6564
BHT-101	CTRP2	5.6632	8.88	2.8423	2.8578
CAL-62	CTRP2	5.8204	7.1968	3.6339	0.2542
FTC-238	CTRP2	6.0789	10.7378	2.2392	4.6522
8305C	CTRP2	6.6643	8.2058	3.5923	0.1171
TT2609-C02	CTRP2	6.9136	12.5128	1.9321	4.8199
FTC-133	CTRP2	8.2525	18.8584	-0.1823	10.712
8505C	CTRP2	9.1457	29.0426	-4.4671	21.0364

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CAL-33	CTRP2	0.1346	1.5653	0.1316	26.3189
HSC-2	CTRP2; CTRP1	3.6649	6.7539	2.8846	11.4874
YD-8	CTRP2	4.0814	10.661	0.7956	13.7033
HSC-4	CTRP2	4.5184	7.3527	2.7986	4.636
SNU-1214	CTRP2	4.5791	8.0686	2.4903	5.8163
FaDu	CTRP2	4.618	6.1654	3.4505	1.8083
HSC-3	CTRP2	4.8147	7.2222	3.077	3.0292
PE/CA-PJ15	CTRP2	4.851	7.3247	3.0525	3.0757
SCC-4	CTRP2	4.9819	11.3218	1.186	10.4875
BICR 18	CTRP2	5.0007	8.7011	2.4904	5.1364
SNU-899	CTRP2	5.1157	7.0225	3.3624	1.5412
BICR 22	CTRP2	5.163	8.8466	2.5337	4.7187
SCC-9	CTRP2; CTRP1	5.2145	10.006	2.7138	8.9635
PE/CA-PJ49	CTRP2	5.2526	7.3411	3.2985	1.6282
YD-10B	CTRP2	5.271	9.3985	2.3419	5.3358
PE/CA-PJ34 (clone C12)	CTRP2	5.2887	8.245	2.9042	3.0738
BHY	CTRP2	5.6429	7.4666	3.4508	0.7889
SNU-1076	CTRP2	5.6455	7.9875	3.2317	1.4793
PE/CA-PJ41 (clone D2)	CTRP2	5.7028	10.6575	2.0316	5.9607
BICR 31	CTRP2	5.8485	8.5294	3.1056	1.7215
Detroit 562	CTRP2	5.9968	7.5097	3.589	0.2777
BICR 6	CTRP2	6.1154	7.2419	3.7272	0.0647
SNU-46	CTRP2	6.2991	7.8837	3.571	0.2185
BICR 16	CTRP2	6.4141	7.8316	3.6316	0.115
BICR 56	CTRP2	6.473	8.3833	3.4573	0.3607
SNU-1041	CTRP2	6.6482	12.0965	1.9625	5.0127
SNU-1066	CTRP2	8.0996	16.216	0.951	7.0081
SCC-25	CTRP2	8.6183	27.8686	-4.2712	21.3252

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
BFTC-905	CTRP2	2.562	5.7442	1.7956	13.0362
CAL-29	CTRP2	2.8615	6.1409	1.9196	11.7799
UM-UC-1	CTRP2	4.0824	8.6449	1.8045	9.5865
RT-4	CTRP2; CTRP1	4.2678	8.8416	2.4737	11.7175
253J	CTRP2	4.4007	7.3287	2.7199	5.1665
VM-CUB-1	CTRP2	4.5647	9.0782	1.9779	7.9731
UM-UC-3	CTRP2; CTRP1	4.8905	10.1343	2.3795	10.8574
TCCSUP	CTRP2	5.0235	11.6406	1.0598	10.9197
BC-3C	CTRP2	5.0877	9.5758	2.1257	6.4929
JMSU-1	CTRP2	5.1055	7.1198	3.3122	1.7374
SCaBER	CTRP2	5.1972	9.2283	2.3729	5.3189
RT-112	CTRP2	5.2634	7.2882	3.3283	1.5099
J82	CTRP2	5.3598	9.0935	2.5489	4.3793
HT-1197	CTRP2	5.632	11.9134	1.375	8.6771
KU-19-19	CTRP2	6.0165	7.3711	3.6468	0.1757
639V	CTRP2	6.1524	11.9118	1.7335	6.5147
5637	CTRP2; CTRP1	6.2013	12.528	2.2284	9.2111
U-BLC1	CTRP2	6.6228	8.0603	3.6272	0.0894
HT-1376	CTRP2; CTRP1	6.875	12.3212	2.807	6.0695
T24	CTRP2	6.9625	14.8931	0.8519	8.7726
KMBC-2	CTRP2; CTRP1	7.2415	14.5427	1.9896	8.5901
647V	CTRP2	8.1415	20.52	-1.0451	13.6282
SW1710	CTRP2	8.7826	32.3721	-6.3582	25.0355

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HeLa	CTRP2	5.6975	7.3824	3.5103	0.5899

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Itraconazole (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Moderate	Decreased absorption of Itraconazole due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[20]
Clindamycin	DM15HL8	Moderate	Decreased metabolism of Itraconazole caused by Clindamycin mediated inhibition of CYP450 enzyme.	Acne vulgaris [ED80]	[21]
Ivosidenib	DM8S6T7	Major	Decreased metabolism of Itraconazole caused by Ivosidenib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[22]
Midostaurin	DMI6E0R	Major	Decreased metabolism of Itraconazole caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[23]
Idarubicin	DMM0XGL	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by Idarubicin.	Acute myeloid leukaemia [2A60]	[24]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Itraconazole caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[25]
Gilteritinib	DMTI0ZO	Major	Decreased metabolism of Itraconazole caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[26]
Oliceridine	DM6MDCF	Major	Decreased metabolism of Itraconazole caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[27]
Ivabradine	DM0L594	Major	Decreased metabolism of Itraconazole caused by Ivabradine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[28]
Dronedarone	DMA8FS5	Major	Decreased metabolism of Itraconazole caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[28]
Bedaquiline	DM3906J	Moderate	Decreased metabolism of Itraconazole caused by Bedaquiline mediated inhibition of CYP450 enzyme.	Antimicrobial drug resistance [MG50-MG52]	[29]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Itraconazole caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[25]
Budesonide	DMJIBAW	Major	Decreased metabolism of Itraconazole caused by Budesonide mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[30]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Itraconazole caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[31]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Itraconazole caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[32]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Itraconazole caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[32]
Cariprazine	DMJYDVK	Major	Decreased metabolism of Itraconazole caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[33]
Erdafitinib	DMI782S	Major	Decreased metabolism of Itraconazole caused by Erdafitinib mediated inhibition of CYP450 enzyme.	Bladder cancer [2C94]	[34]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Itraconazole caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[35]
Talazoparib	DM1KS78	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[25]
Ixabepilone	DM2OZ3G	Moderate	Decreased metabolism of Itraconazole caused by Ixabepilone mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[36]
Lapatinib	DM3BH1Y	Major	Decreased metabolism of Itraconazole caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
HKI-272	DM6QOVN	Major	Decreased metabolism of Itraconazole caused by HKI-272 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[37]
LY2835219	DM93VBZ	Major	Decreased metabolism of Itraconazole caused by LY2835219 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[38]
Esterified estrogens	DM9KZDO	Moderate	Decreased metabolism of Itraconazole caused by Esterified estrogens mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[39]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Itraconazole caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[40]
Quinestrol	DMJ6H1Z	Moderate	Decreased metabolism of Itraconazole caused by Quinestrol mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[39]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Itraconazole caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Bosutinib	DMTI8YE	Major	Decreased metabolism of Itraconazole caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Trastuzumab Emtansine	DMU1LXS	Moderate	Decreased metabolism of Itraconazole caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Macitentan	DMP79A1	Major	Decreased metabolism of Itraconazole caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[41]
PF-04449913	DMSB068	Major	Decreased metabolism of Itraconazole caused by PF-04449913 mediated inhibition of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[42]
Vilanterol	DMF5EK1	Moderate	Decreased metabolism of Itraconazole caused by Vilanterol mediated inhibition of CYP450 enzyme.	Chronic obstructive pulmonary disease [CA22]	[43]
Indacaterol	DMQJHR7	Minor	Decreased metabolism of Itraconazole caused by Indacaterol mediated inhibition of CYP450 enzyme.	Chronic obstructive pulmonary disease [CA22]	[44]
Levomilnacipran	DMV26S8	Major	Decreased metabolism of Itraconazole caused by Levomilnacipran mediated inhibition of CYP450 enzyme.	Chronic pain [MG30]	[45]
Fidaxomicin	DMFP6MV	Minor	Decreased clearance of Itraconazole due to the transporter inhibition by Fidaxomicin.	Clostridium difficile enterocolitis [1A04]	[28]
Regorafenib	DMHSY1I	Moderate	Decreased metabolism of Itraconazole caused by Regorafenib mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[28]
Intedanib	DMSTA36	Moderate	Decreased metabolism of Itraconazole caused by Intedanib mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[46]
Drospirenone	DM1A9W3	Major	Decreased metabolism of Itraconazole caused by Drospirenone mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[28]
Levonorgestrel	DM1DP7T	Moderate	Decreased metabolism of Itraconazole caused by Levonorgestrel mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[39]
Osilodrostat	DMIJC9X	Major	Decreased metabolism of Itraconazole caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[25]
Ivacaftor	DMZC1HS	Major	Decreased metabolism of Itraconazole caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[28]
Rivaroxaban	DMQMBZ1	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Rivaroxaban.	Deep vein thrombosis [BD71]	[28]
Escitalopram	DMFK9HG	Minor	Decreased metabolism of Itraconazole caused by Escitalopram mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[47]
OPC-34712	DMHG57U	Major	Decreased metabolism of Itraconazole caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[48]
Clomipramine	DMINRKW	Moderate	Decreased metabolism of Itraconazole caused by Clomipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[32]
Polatuzumab vedotin	DMF6Y0L	Major	Decreased metabolism of Itraconazole caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[49]
[3H]estrone-3-sulphate	DMGPF0N	Moderate	Decreased metabolism of Itraconazole caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[50]
Ospemifene	DMC4GEI	Moderate	Decreased metabolism of Itraconazole caused by Ospemifene mediated inhibition of CYP450 enzyme.	Dyspareunia [GA12]	[51]
Ingrezza	DMVPLNC	Major	Additive CNS depression effects by the combination of Itraconazole and Ingrezza.	Dystonic disorder [8A02]	[52]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Itraconazole caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[53]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Itraconazole caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Lacosamide	DMVM6QR	Moderate	Decreased metabolism of Itraconazole caused by Lacosamide mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Itraconazole caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[25]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Itraconazole caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Cannabidiol	DM0659E	Minor	Decreased metabolism of Itraconazole caused by Cannabidiol mediated inhibition of CYP450 enzyme.	Epileptic encephalopathy [8A62]	[25]
Bay 80-6946	DMLOS5R	Major	Decreased metabolism of Itraconazole caused by Bay 80-6946 mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[54]
Tazemetostat	DMWP1BH	Major	Decreased metabolism of Itraconazole caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[55]
Solifenacin	DMG592Q	Major	Decreased metabolism of Itraconazole caused by Solifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[28]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Itraconazole caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[56]
Dexlansoprazole	DM1DBV5	Moderate	Decreased absorption of Itraconazole due to altered gastric pH caused by Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[57]
Ripretinib	DM958QB	Major	Decreased metabolism of Itraconazole caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[28]
Sunitinib	DMCBJSR	Moderate	Decreased metabolism of Itraconazole caused by Sunitinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[28]
Avapritinib	DMK2GZX	Major	Decreased metabolism of Itraconazole caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[25]
Colchicine	DM2POTE	Major	Decreased metabolism of Itraconazole caused by Colchicine mediated inhibition of CYP450 enzyme.	Gout [FA25]	[58]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Itraconazole caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[59]
Simeprevir	DMLUA9D	Major	Decreased metabolism of Itraconazole caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[28]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Itraconazole caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[59]
Daclatasvir	DMSFK9V	Major	Decreased metabolism of Itraconazole caused by Daclatasvir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[25]
Rifapentine	DMCHV4I	Major	Increased metabolism of Itraconazole caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[60]
Brentuximab vedotin	DMWLC57	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[61]
MK-1439	DM215WE	Minor	Decreased metabolism of Itraconazole caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Itraconazole caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[64]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Itraconazole caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[65]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Itraconazole caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[66]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Itraconazole caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Rilpivirine	DMJ0QOW	Moderate	Increased metabolism of Itraconazole caused by Rilpivirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[67]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Itraconazole caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Maraviroc	DMTL94F	Major	Decreased metabolism of Itraconazole caused by Maraviroc mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[68]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Itraconazole and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[69]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Itraconazole and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[70]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Itraconazole caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[28]
Sodium zirconium cyclosilicate	DMCSLZ4	Moderate	Decreased absorption of Itraconazole due to altered gastric pH caused by Sodium zirconium cyclosilicate.	Hyperkalaemia [5C76]	[25]
Aliskiren	DM1BV7W	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Aliskiren.	Hypertension [BA00-BA04]	[28]
Tolvaptan	DMIWFRL	Major	Decreased metabolism of Itraconazole caused by Tolvaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[28]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Itraconazole caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[71]
TP-434	DM5A31S	Minor	Decreased metabolism of Itraconazole caused by TP-434 mediated inhibition of CYP450 enzyme.	Infectious gastroenteritis/colitis [1A40]	[72]
Berotralstat	DMWA2DZ	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Berotralstat.	Innate/adaptive immunodeficiency [4A00]	[73]
Suvorexant	DM0E6S3	Major	Decreased metabolism of Itraconazole caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[28]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Itraconazole caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[74]
ITI-007	DMUQ1DO	Major	Decreased metabolism of Itraconazole caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[75]
Eluxadoline	DMYZ0P1	Moderate	Decreased metabolism of Itraconazole caused by Eluxadoline mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[76]
Naloxegol	DML0B41	Major	Decreased metabolism of Itraconazole caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[28]
Pemigatinib	DM819JF	Major	Decreased metabolism of Itraconazole caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[25]
Crizotinib	DM4F29C	Major	Decreased metabolism of Itraconazole caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[28]
Brigatinib	DM7W94S	Major	Decreased metabolism of Itraconazole caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[77]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Itraconazole caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[78]
PF-06463922	DMKM7EW	Major	Decreased metabolism of Itraconazole caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[79]
Osimertinib	DMRJLAT	Major	Decreased metabolism of Itraconazole caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[80]
Pralsetinib	DMWU0I2	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Pralsetinib.	Lung cancer [2C25]	[81]
Capmatinib	DMYCXKL	Major	Decreased metabolism of Itraconazole caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[82]
Selpercatinib	DMZR15V	Major	Decreased metabolism of Itraconazole caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[25]
Halofantrine	DMOMK1V	Major	Decreased metabolism of Itraconazole caused by Halofantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[83]
Hydroxychloroquine	DMSIVND	Moderate	Decreased metabolism of Itraconazole caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[28]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Itraconazole and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[84]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Itraconazole and Idelalisib.	Mature B-cell leukaemia [2A82]	[85]
GDC-0199	DMH0QKA	Major	Decreased metabolism of Itraconazole caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[86]
Acalabrutinib	DM7GCVW	Major	Decreased metabolism of Itraconazole caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[87]
Ibrutinib	DMHZCPO	Major	Decreased metabolism of Itraconazole caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[28]
Ponatinib	DMYGJQO	Major	Decreased metabolism of Itraconazole caused by Ponatinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[28]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[28]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Itraconazole caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[88]
Selumetinib	DMC7W6R	Major	Decreased metabolism of Itraconazole caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[89]
Ubrogepant	DM749I3	Major	Decreased metabolism of Itraconazole caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[90]
Rimegepant	DMHOAUG	Moderate	Decreased metabolism of Itraconazole caused by Rimegepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[91]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Itraconazole caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[92]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Itraconazole due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[70]
Flibanserin	DM70DTN	Major	Decreased metabolism of Itraconazole caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[93]
Panobinostat	DM58WKG	Major	Decreased metabolism of Itraconazole caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[94]
Siponimod	DM2R86O	Major	Decreased metabolism of Itraconazole caused by Siponimod mediated inhibition of CYP450 enzyme.	Multiple sclerosis [8A40]	[28]
Deflazacort	DMV0RNS	Major	Decreased metabolism of Itraconazole caused by Deflazacort mediated inhibition of CYP450 enzyme.	Muscular dystrophy [8C70]	[25]
Romidepsin	DMT5GNL	Moderate	Decreased metabolism of Itraconazole caused by Romidepsin mediated inhibition of CYP450 enzyme.	Mycosis fungoides [2B01]	[95]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of Itraconazole caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[25]
Nilotinib	DM7HXWT	Major	Decreased metabolism of Itraconazole caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[28]
Ruxolitinib	DM7Q98D	Major	Decreased metabolism of Itraconazole caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[96]
Dasatinib	DMJV2EK	Major	Decreased metabolism of Itraconazole caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[28]
Vorapaxar	DMA16BR	Major	Decreased metabolism of Itraconazole caused by Vorapaxar mediated inhibition of CYP450 enzyme.	Myocardial infarction [BA41-BA43]	[28]
E-2007	DMJDYNQ	Minor	Decreased metabolism of Itraconazole caused by E-2007 mediated inhibition of CYP450 enzyme.	Neuropathy [8C0Z]	[25]
Levomethadyl Acetate	DM06HG5	Major	Decreased metabolism of Itraconazole caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[97]
S-297995	DM26IH8	Moderate	Decreased metabolism of Itraconazole caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[25]
Olaparib	DM8QB1D	Major	Decreased metabolism of Itraconazole caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[28]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Itraconazole caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[98]
MK-4827	DMLYGH4	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by MK-4827.	Ovarian cancer [2C73]	[99]
Istradefylline	DM20VSK	Major	Decreased metabolism of Itraconazole caused by Istradefylline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[100]
Pimavanserin	DMR7IVC	Major	Decreased metabolism of Itraconazole caused by Pimavanserin mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[101]
Bromocriptine	DMVE3TK	Moderate	Decreased metabolism of Itraconazole caused by Bromocriptine mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[32]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Itraconazole caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[102]
Lefamulin	DME6G97	Major	Decreased metabolism of Itraconazole caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[103]
Ergonovine	DM0VEC1	Major	Decreased metabolism of Itraconazole caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[104]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Itraconazole caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[105]
ABIRATERONE	DM8V75C	Minor	Decreased metabolism of Itraconazole caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[106]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Itraconazole caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[107]
Relugolix	DMK7IWL	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Relugolix.	Prostate cancer [2C82]	[108]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[109]
Silodosin	DMJSBT6	Major	Decreased metabolism of Itraconazole caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[28]
Finasteride	DMWV3TZ	Moderate	Decreased metabolism of Itraconazole caused by Finasteride mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[32]
Ambrisentan	DMD1QXW	Minor	Decreased metabolism of Itraconazole caused by Ambrisentan mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[110]
Riociguat	DMXBLMP	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Riociguat.	Pulmonary hypertension [BB01]	[28]
Axitinib	DMGVH6N	Major	Decreased metabolism of Itraconazole caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[28]
Temsirolimus	DMS104F	Major	Increased metabolism of Itraconazole caused by Temsirolimus mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[28]
Ciclesonide	DM2NA4K	Moderate	Decreased metabolism of Itraconazole caused by Ciclesonide mediated inhibition of CYP450 enzyme.	Respiratory system disease [CB40-CB7Z]	[111]
Upadacitinib	DM32B5U	Major	Decreased metabolism of Itraconazole caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[112]
Dexamethasone	DMMWZET	Moderate	Decreased metabolism of Itraconazole caused by Dexamethasone mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[111]
Quetiapine	DM1N62C	Major	Decreased metabolism of Itraconazole caused by Quetiapine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[113]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Itraconazole caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[114]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Itraconazole and Amisulpride.	Schizophrenia [6A20]	[28]
Avanafil	DM75CXN	Major	Decreased metabolism of Itraconazole caused by Avanafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[28]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Itraconazole caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[115]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Itraconazole caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[25]
Larotrectinib	DM26CQR	Major	Decreased metabolism of Itraconazole caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[28]
Ifosfamide	DMCT3I8	Moderate	Decreased metabolism of Itraconazole caused by Ifosfamide mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[32]
Docetaxel	DMDI269	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[116]
Trabectedin	DMG3Y89	Major	Decreased metabolism of Itraconazole caused by Trabectedin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[28]
Armodafinil	DMGB035	Minor	Decreased metabolism of Itraconazole caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[28]
LEE011	DMMX75K	Major	Decreased metabolism of Itraconazole caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[25]
Vandetanib	DMRICNP	Minor	Decreased metabolism of Itraconazole caused by Vandetanib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[117]
Taxol	DMUOT9V	Moderate	Decreased metabolism of Itraconazole caused by Taxol mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[118]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Itraconazole caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[25]
Pomalidomide	DMTGBAX	Moderate	Decreased metabolism of Itraconazole caused by Pomalidomide mediated inhibition of CYP450 enzyme.	Systemic sclerosis [4A42]	[28]
Fostamatinib	DM6AUHV	Major	Decreased metabolism of Itraconazole caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[119]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[98]
As-1670542	DMV05SW	Moderate	Decreased metabolism of Itraconazole caused by As-1670542 mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[25]
Apixaban	DM89JLN	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Apixaban.	Thrombosis [DB61-GB90]	[28]
Brilinta	DMBR01X	Major	Decreased metabolism of Itraconazole caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[28]
Cabozantinib	DMIYDT4	Major	Decreased metabolism of Itraconazole caused by Cabozantinib mediated inhibition of CYP450 enzyme.	Thyroid cancer [2D10]	[28]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Itraconazole caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[25]
Elagolix	DMB2C0E	Major	Decreased metabolism of Itraconazole caused by Elagolix mediated inhibition of CYP450 enzyme.	Uterine fibroid [2E86]	[120]
Fluticasone	DMGCSVF	Major	Decreased metabolism of Itraconazole caused by Fluticasone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[121]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Itraconazole caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[122]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 22	E00206	11048	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Poloxamer 188	E00645	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 20000	E00650	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Itraconazole 100 mg capsule	100 mg	Oral Capsule	Oral
Itraconazole 200 mg tablet	200 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Itraconazole FDA Label
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076104.
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [9] Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther Drug Monit. 2006 Feb;28(1):73-5.
• [10] Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos. 2010 Jun;38(6):923-9.
• [11] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [12] Inhibition of 11-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole. Biochem Pharmacol. 2017 Apr 15;130:93-103. doi: 10.1016/j.bcp.2017.01.010. Epub 2017 Jan 25.
• [13] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [14] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [15] Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines. Toxicol Sci. 2007 May;97(1):32-43.
• [16] Itraconazole cis-diastereoisomers activate aryl hydrocarbon receptor AhR and pregnane X receptor PXR and induce CYP1A1 in human cell lines and human hepatocytes. Toxicology. 2017 May 15;383:40-49.
• [17] Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis. J Invest Dermatol. 2001 Dec;117(6):1635-46. doi: 10.1046/j.0022-202x.2001.01566.x.
• [18] Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
• [19] Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos. 2008 Feb;36(2):339-48.
• [20] Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8. [PMID: 6282204]
• [21] Product Information. Cleocin (clindamycin). Pharmacia and Upjohn, Kalamazoo, MI.
• [22] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [23] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
• [24] Multum Information Services, Inc. Expert Review Panel.
• [25] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [26] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [27] Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
• [28] Cerner Multum, Inc. "Australian Product Information.".
• [29] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [30] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
• [31] Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
• [32] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
• [33] Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
• [34] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [35] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [36] Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
• [37] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
• [38] Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
• [39] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
• [40] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [41] Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
• [42] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [43] Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
• [44] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [45] Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
• [46] Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
• [47] Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
• [48] Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
• [49] Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
• [50] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
• [51] Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
• [52] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [53] Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
• [54] Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
• [55] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [56] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [57] Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91. [PMID: 9357389]
• [58] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
• [59] Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
• [60] Abadie-Kemmerly S, Pankey GA, Dalvisio JR "Failure of ketoconazole treatment of blastomyces dermatidis due to interaction of isoniazid and rifampin." Ann Intern Med 109 (1988): 844-5. [PMID: 3190036]
• [61] Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
• [62] Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
• [63] Polk RE, Crouch MA, Israel DS, et al. "Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men." Pharmacotherapy 19 (1999): 1378-84. [PMID: 10600086]
• [64] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [65] Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
• [66] Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
• [67] Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
• [68] Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [69] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [70] Canadian Pharmacists Association.
• [71] Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
• [72] Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
• [73] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [74] Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
• [75] Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
• [76] Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
• [77] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [78] Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
• [79] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [80] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [81] Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
• [82] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [83] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [84] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [85] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [86] Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
• [87] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [88] Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
• [89] Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [90] Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
• [91] Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
• [92] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [93] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [94] Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
• [95] Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
• [96] Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
• [97] Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
• [98] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [99] Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
• [100] Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
• [101] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [102] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [103] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [104] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7. [PMID: 10616689]
• [105] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [106] Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
• [107] Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
• [108] Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
• [109] Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
• [110] Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
• [111] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [112] Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
• [113] DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
• [114] Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
• [115] Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
• [116] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
• [117] Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
• [118] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
• [119] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [120] Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
• [121] Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
• [122] Product Information. Rythmol SR (propafenone). GlaxoSmithKline, Research Triangle Park, NC.